15
May

08:30 AM ET

Medicinal Chemistry

Name: Medicinal Chemistry Strategy Meeting East Coast 2024
Start: 2024-05-15T08:00
End: 2024-05-15T18:00
Location: Hyatt Regency Princeton

Strategy Meeting East Coast USA 2024

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Hyatt Regency Princeton

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Princeton, New Jersey, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Abhijat Vatsyayan

Head of AI and Innovation Taiho Oncology

Andrew Zhang

Director, Head of Chemical Biology AstraZeneca

Christopher Conway

President, Research and Development Curia

Chris is a seasoned business executive with a 25 year strong track record across a variety of industry verticals including aerospace, pharmaceutical/biotech and contract research, development, and manufacturing. Chris is highly experienced in P&L leadership, sales, and marketing having worked in large and small, public and private equity backed companies. Currently, Chris serves as President and R&D Business Unit Head at Curia, a global top ten organization in contract research, development and manufacturing services, serving the pharmaceutical/biotech industry. Chris also currently serves as a Director on the board of two Life Sciences organizations including Viyash Life Sciences Private Limited, a Carlyle owned company, as well as the Drug, Chemical & Associated Technologies Association, Inc. (DCAT). Chris received his B.S. in Marketing & Management from Siena College and his Doctorate of Humane Letters from the Albany College of Pharmacy and Health Sciences

Mark Wolf

Director, Medicinal Chemistry Curia

Mark Wolf, Ph.D. is Director of Medicinal Chemistry at Curia and has over 27 years of drug discovery and development experience. He has led interdisciplinary scientific teams to support large pharma, biotech collaborations and Curia R&D programs. His research has spanned several therapeutic areas including oncology, CNS, pain/inflammation, and respiratory. Mark has experience establishing practical screening strategies to identify drug candidate compounds with a first-in-class or best-in-class product profile. He led Curia’s Tubulin Inhibitor Program which discovered and advancedALB-109564 into a Phase 1 clinical trial for the treatment of solid tumors. His CNS experience includes targets in the areas of pain management (GPCR targets) and antipsychotics based on the hypoglutamate hypothesis (GlyT1 inhibitors). Mark has extensive experience managing multiple external providers and Curia assets in support of discovery and pre clinical development programs. He is named as an inventor/co-inventor on five patents and co-author on 25 peer reviewed publications.

Matthew Surman

Associate Director, Medicinal Chemistry Curia

Matt Surman, Ph.D. is Associate Director of Medicinal Chemistry at Curia Global and has over 20 years of industry experience. He joined the Curia Medicinal Chemistry department in 2002 and worked on contract research projects spanning a variety of therapeutic areas including oncology, anti-infectives and CNS disorders. From 2005 to 2011, he was part of the Curia internal Discovery Research and Development department. His efforts were focused in the area of metabolic disorders, particularly in obesity. He served as the project leader for the Curia MCH-1 antagonist program from 2008 until returning to the Medicinal Chemistry department in late 2011. During that time, the project culminated in the discovery and development of a successful Phase I clinical candidate. Since returning to the Medicinal Chemistry department, Dr. Surman has led the discovery efforts on a number of programs including projects involved in oncology, neurological disease, and pain. Multiple pre-clinical and clinical candidates have arisen from these efforts. Dr. Surman has over 40 peer reviewed publications and patent applications

Helena Almqvist

Project Advisor, Business Development Pelago Bioscience

Rick Ewing

VP, Head of Chemistry Rapafusyn Pharmaceuticals

Rick Ewing is VP, Head of Chemistry at Rapafusyn, a platform company focused on Type I molecular glues. Previous to Rapafusyn, Rick held the position of VP, Head of Drug Discovery at the Barer Institute. Prior to Barer, Rick was a senior director in Discovery Chemistry at Bristol Myers Squibb where he led medicinal chemistry teams to deliver 15 development candidates in the therapeutic areas of cardiovascular, diabetes, obesity, and heart failure. Among the development candidates is Milvexian, a first in class Factor XIa inhibitor currently in PIII 
development. Rick is coinventor on 79 patents, and co-author on 77 publications. In 2023, Rick was awarded the ACS Philadelphia Section Award for distinguished achievement in medicinal chemistry. In 2023, Rick also received the Edison Patent Award in Biotechnology Innovation with colleagues from BMS and Scripps Research. In 2021, he was awarded the ACS Fellow by the American 
Chemical Society and in 2018 received the Ondetti-Cushman award for leadership of the FXIa drug discovery team. Prior to Bristol Myers Squibb, Rick spent 12 years at RPR (now Sanofi). Rick received his Ph.D. in Organic Chemistry from U. Penn.

Danny Talati

VP, Corportate Development Psychogenics

David James

Senior VP Business Development eMolecules

Ernane Souza, PhD, RPh

Assistant Director, Translational PKPD and DMPK Supernus Pharmaceuticals Inc

Eileen Carry

Chief Scientific Officer Zena Therapeutics Inc

Frank Leu

Founder & Managing Member/ Managing Member BioPharMatrix LLC/ Novapeutics LLC

Gunaretnam Rajagopal

Venture Partner Samsara Biocapital

Guna has experience in applying Informatics & Analytics across the entire drug discovery & development pipeline to advance the search and development of safe and effective medicines. His training and expertise encompass the fields of Data Sciences, AI/Machine Learning, Bioinformatics, Computational, Systems Biology & Pharmacology, Genetics & Genomics, High Performance Computing and Theoretical & Computational Physics. He received his PhD in Computational & Theoretical Physics from Georgia Tech in 1991. Guna was an Assistant Director of Research at the Cavendish (1996-2000) and elected a Fellow of Jesus College Cambridge (1996-2000). He moved to Singapore to be the founding Executive Director of the Bioinformatics Institute (2000-2007) that coordinated and supported biomedical computing & informatics supporting public & pharmaceutical R&D institutes at the BIOPOLIS. In 2008, he moved to Rutgers University to head the Bioinformatics & Systems Biology program at the Rutgers Cancer Institute of New Jersey (a NCI-designated comprehensive cancer center), with a joint appointment as Adjunct Professor at the Robert Wood Johnson Medical School and as a Member of the School of Natural Sciences, Institute for Advanced Studies in Princeton (2007-2012). In 2012, he was recruited to Johnson & Johnson to lead efforts to develop and deploy Computational, Informatics and Data Science infrastructure & capabilities to support global programs in basic, clinical, translational research across all therapeutic and functional areas. After ten years at J&J,

Huijun Wang

Head of Computational Drug Design Deerfield Management

ML Ujwal

Associate Director, Data Science Johnson & Johnson

Jim LaRocque

Senior Research Scientist III, Assay Development & Screening Curia

James LaRocque, Senior Research Scientist III, is leading a team of Curia’s biologists focused on providing state of the art screening and compound characterization platforms, including high content screening and cellular imaging analysis along with traditional cellular and biochemical technologies and label free screening by mass spectrometry detection as part of Curia’s integrated drug discovery center in Buffalo, NY. Previously he focused on the development and implementation of screening platform technologies and led characterization initiatives to identify selective inhibitors of critical Ubiquitin pathway enzymes. He led efforts in assay development, compound management, screening and hit characterization on hundreds of exploratory projects for Wyeth over his 20 year career which started with antiviral research and later diversified in to a wide variety of therapeutic areas while contributing to Wyeth’s and later Pfizer’s lead identification programs.

Tanweer Khan

Senior Director, Head of Discovery Chemistry aTai Life Sciences

Dongming Shen

Former Vice President, Chemistry Viva Star Biosciences

Yushma Bhurruth-Alcor

Executive Director, Chemistry Remedy Plan Therapeutics

First name	Last name	Job title	Company name	Photo URL	Bio Position
Abhijat	Vatsyayan	Head of AI and Innovation	Taiho Oncology	https://proventainternational.com/wp-content/uploads/2023/03/Abhijat-Vatsyayan.jpg	Trained as an aerospace engineer Abhijat has had a career spanning over 23 years most of it dedicated to helping to bring life extending medicines to patients through the use of technology in this 20 years working at pharmaceutical companies he collaborates with individuals from diverse backgrounds applying analytical design and creative problem solving skills to the complex challenge of drug development abhijat also has a foundational understanding of artificial intelligence including machine learning and has built simplified deep learning frameworks to educate and present machine learning concepts finally he is also a proud co founder of multiple failed startups.
Andrew	Zhang	Director, Head of Chemical Biology	AstraZeneca	https://proventainternational.com/wp-content/uploads/2024/04/Andrew-Zhang.jpg	Andrew Zhang is the Director and Head of Chemical Biology at AstraZeneca. He joined AstraZeneca in 2013 and his team’s remit is using chemical probes and mass spectrometry-based discovery proteomics for deconvoluting the mechanism of drug target engagement towards identifying drivers of efficacy and adverse safety events. Andrew’s scientific career started at the University of California, Berkeley, where he obtained a B.S. in Chemistry and a B.A. in Molecular and Cell Biology, and he received his Ph.D. with Professor David Spiegel at Yale working on small molecule immunomodulators. Andrew trained as a postdoctoral fellow at the Ontario Institute for Cancer Research (Toronto, Canada) with Dr. Rima Al-awar.
Christopher	Conway	President, Research and Development	Curia	https://proventainternational.com/wp-content/uploads/2024/04/Chris-Conway.jpg	Chris is a seasoned business executive with a 25 year strong track record across a variety of industry verticals including aerospace, pharmaceutical/biotech and contract research, development, and manufacturing. Chris is highly experienced in P&L leadership, sales, and marketing having worked in large and small, public and private equity backed companies. Currently, Chris serves as President and R&D Business Unit Head at Curia, a global top ten organization in contract research, development and manufacturing services, serving the pharmaceutical/biotech industry. Chris also currently serves as a Director on the board of two Life Sciences organizations including Viyash Life Sciences Private Limited, a Carlyle owned company, as well as the Drug, Chemical & Associated Technologies Association, Inc. (DCAT). Chris received his B.S. in Marketing & Management from Siena College and his Doctorate of Humane Letters from the Albany College of Pharmacy and Health Sciences
Mark	Wolf	Director, Medicinal Chemistry	Curia	https://proventainternational.com/wp-content/uploads/2024/04/Mark-Wolf.jpg	Mark Wolf, Ph.D. is Director of Medicinal Chemistry at Curia and has over 27 years of drug discovery and development experience. He has led interdisciplinary scientific teams to support large pharma, biotech collaborations and Curia R&D programs. His research has spanned several therapeutic areas including oncology, CNS, pain/inflammation, and respiratory. Mark has experience establishing practical screening strategies to identify drug candidate compounds with a first-in-class or best-in-class product profile. He led Curia’s Tubulin Inhibitor Program which discovered and advancedALB-109564 into a Phase 1 clinical trial for the treatment of solid tumors. His CNS experience includes targets in the areas of pain management (GPCR targets) and antipsychotics based on the hypoglutamate hypothesis (GlyT1 inhibitors). Mark has extensive experience managing multiple external providers and Curia assets in support of discovery and pre clinical development programs. He is named as an inventor/co-inventor on five patents and co-author on 25 peer reviewed publications.
Matthew	Surman	Associate Director, Medicinal Chemistry	Curia	https://proventainternational.com/wp-content/uploads/2024/04/matthew-surman.jpg	Matt Surman, Ph.D. is Associate Director of Medicinal Chemistry at Curia Global and has over 20 years of industry experience. He joined the Curia Medicinal Chemistry department in 2002 and worked on contract research projects spanning a variety of therapeutic areas including oncology, anti-infectives and CNS disorders. From 2005 to 2011, he was part of the Curia internal Discovery Research and Development department. His efforts were focused in the area of metabolic disorders, particularly in obesity. He served as the project leader for the Curia MCH-1 antagonist program from 2008 until returning to the Medicinal Chemistry department in late 2011. During that time, the project culminated in the discovery and development of a successful Phase I clinical candidate. Since returning to the Medicinal Chemistry department, Dr. Surman has led the discovery efforts on a number of programs including projects involved in oncology, neurological disease, and pain. Multiple pre-clinical and clinical candidates have arisen from these efforts. Dr. Surman has over 40 peer reviewed publications and patent applications
Helena Almqvist		Project Advisor, Business Development	Pelago Bioscience	https://proventainternational.com/wp-content/uploads/2024/04/Helena-Almqvist.jpg	Helena Almqvist is a Project Advisor at Pelago Bioscience, where she acts as a scientific liaison for key accounts and develops customized projects. With more than 15 years of experience in pre-clinical drug discovery, she joined the company in 2018 to accelerate the CETSA® HT screening platform and lead CETSA projects tailored to clients. Helena is an expert in assay development and screening, having worked in small and large pharma settings as well as a project manager at a national infrastructure. She played a crucial role in adapting the CETSA method for screening and executing the first primary screening campaign using CETSA.
Rick	Ewing	VP, Head of Chemistry	Rapafusyn Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2024/04/Rick-Ewing.jpg	Rick Ewing is VP, Head of Chemistry at Rapafusyn, a platform company focused on Type I molecular glues. Previous to Rapafusyn, Rick held the position of VP, Head of Drug Discovery at the Barer Institute. Prior to Barer, Rick was a senior director in Discovery Chemistry at Bristol Myers Squibb where he led medicinal chemistry teams to deliver 15 development candidates in the therapeutic areas of cardiovascular, diabetes, obesity, and heart failure. Among the development candidates is Milvexian, a first in class Factor XIa inhibitor currently in PIII development. Rick is coinventor on 79 patents, and co-author on 77 publications. In 2023, Rick was awarded the ACS Philadelphia Section Award for distinguished achievement in medicinal chemistry. In 2023, Rick also received the Edison Patent Award in Biotechnology Innovation with colleagues from BMS and Scripps Research. In 2021, he was awarded the ACS Fellow by the American Chemical Society and in 2018 received the Ondetti-Cushman award for leadership of the FXIa drug discovery team. Prior to Bristol Myers Squibb, Rick spent 12 years at RPR (now Sanofi). Rick received his Ph.D. in Organic Chemistry from U. Penn.
Danny	Talati	VP, Corportate Development	Psychogenics	https://proventainternational.com/wp-content/uploads/2024/05/Danny-Talati.jpg
David	James	Senior VP Business Development	eMolecules	https://proventainternational.com/wp-content/uploads/2024/04/David-James.jpg	David is responsible for scientific business development working closely with new and existing Chemistry departments to design efficient chemistry operations solutions using eMolecules platforms and capabilities. David has been with eMolecules for over 10 years in a variety of roles, including Corporate Development, Product Development and Sales resulting in high growth for the company. Before joining eMolecules, David was a medicinal chemist with Synta Pharmaceuticals and was a member of research teams that produced three successful IND submissions. David has a Ph.D. in organic chemistry from Queensland University of Technology in Brisbane, Australia.
Ernane	Souza, PhD,	Assistant Director, Translational PKPD and DMPK	Supernus Pharmaceuticals Inc	https://proventainternational.com/wp-content/uploads/2024/04/Ernane-Souza.jpg	Dr. Ernane Souza works as an Assistant Director at Supernus Pharmaceuticals. His responsibilities comprise multiple stages of preclinical drug development, from computer aided drug-design to DMPK, PBPK modeling, all the way to first-in-human clinical trials. He is a licensed pharmacist and medicinal chemist. Prior to transitioning to the pharmaceutical industry, he managed his independent research lab in academia, where he led the development of a new class of anticoagulants while teaching ADME and MedChem to professional student pharmacists. He is familiar with intellectual property law and is the primary inventor in pending patents related to novel drug candidates.
Eileen	Carry	Chief Scientific Officer	Zena Therapeutics Inc	https://proventainternational.com/wp-content/uploads/2024/01/Eileen-carry.png	Eileen Carry, PhD is founder and Chief Scientific Officer of Zena Therapeutics Inc. Zena Therapeutics is a drug discovery company, spun-out of Rutgers University, designing new medications for mental health and addiction by improving safety profiles. Currently the Zena’s research, funded by a phase I NIH STTR grant, focuses on acute anxiolytic compounds that do not increase the risk of overdose if taken concomitantly with other CNS depressing substances such as opioids and alcohol. Dr. Carry is determined to pave the way for improving the safety of CNS pharmaceuticals by minimizing harm caused by misuse.
Frank	Leu	Founder & Managing Member/ Managing Member	BioPharMatrix LLC/ Novapeutics LLC	https://proventainternational.com/wp-content/uploads/2020/08/Frank-Leu-1.jpg	Frank Leu is a Founder & Managing Member/ Managing Member of BioPharMatrix LLC/ Novapeutics LLC located in Philadelphia, developing a first-in-class insulin-producing beta-cell restoration curative for diabetes. Prior, Frank was at a specialty pharma, Verto Institute, developing curatives for a neuroendocrine cancer. Frank received his Pharmacology Ph.D. from Weill Cornell Graduate School of Medical Sciences, postdoc-ed at a HHMI lab at the Rockefeller University, and served as an instructor at the Rutgers Cancer Institute of NJ. Currently, he is an adjunct professor at Thomas Jefferson University, advisor to 1776 for Pennovation Center Labs, founder of BioPharMatrix (life-science ecosystem), and serving on numerous life-sciences advisory boards.
Gunaretnam	Rajagopal	Venture Partner	Samsara Biocapital	https://proventainternational.com/wp-content/uploads/2022/08/Gunaretnam-Rajagopal.jpg	Guna has experience in applying Informatics & Analytics across the entire drug discovery & development pipeline to advance the search and development of safe and effective medicines. His training and expertise encompass the fields of Data Sciences, AI/Machine Learning, Bioinformatics, Computational, Systems Biology & Pharmacology, Genetics & Genomics, High Performance Computing and Theoretical & Computational Physics. He received his PhD in Computational & Theoretical Physics from Georgia Tech in 1991. Guna was an Assistant Director of Research at the Cavendish (1996-2000) and elected a Fellow of Jesus College Cambridge (1996-2000). He moved to Singapore to be the founding Executive Director of the Bioinformatics Institute (2000-2007) that coordinated and supported biomedical computing & informatics supporting public & pharmaceutical R&D institutes at the BIOPOLIS. In 2008, he moved to Rutgers University to head the Bioinformatics & Systems Biology program at the Rutgers Cancer Institute of New Jersey (a NCI-designated comprehensive cancer center), with a joint appointment as Adjunct Professor at the Robert Wood Johnson Medical School and as a Member of the School of Natural Sciences, Institute for Advanced Studies in Princeton (2007-2012). In 2012, he was recruited to Johnson & Johnson to lead efforts to develop and deploy Computational, Informatics and Data Science infrastructure & capabilities to support global programs in basic, clinical, translational research across all therapeutic and functional areas. After ten years at J&J,
Huijun	Wang	Head of Computational Drug Design	Deerfield Management	https://proventainternational.com/wp-content/uploads/2023/05/Huijun-Wang.jpg	Huijun Wang, Ph.D., is the Head of Computational Drug Design, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Wang was most recently Director, Computational Drug Design at Agios Pharmaceuticals. Before Agios, she was an Associate Principal Scientist, Modeling and Informatics at Merck and a Senior Scientist at Pfizer. Dr. Wang is an expertise in computational drug design including chemical biology, virtual screening, AI/ML, structure/ligand-based design, ADMET prediction, etc. Dr. Wang has over 18 years experiences in AI/ML, NLP, FAIR data management, cheminformatics, bioinformatics, and their applications in drug discovery.
ML	Ujwal	Associate Director, Data Science	Johnson & Johnson	https://proventainternational.com/wp-content/uploads/2023/11/ML-Ujwal-Janssen.jpg	ML Ujwal PhD leads the PSTS/Data Science at Janssen R&D (J&J). He is a proven scientific leader with a strong pedigree in Drug Discovery and Applied Machine Learning. He has 15+ years of experience in academia, biotech, and large pharma. Before joining Janssen R&D, he co-founded and was the head of Data Sciences at Inciton, an early-stage startup that used MD simulations and ML approaches. Earlier he led predictive toxicology efforts at Eli Lilly & Co. He was on staff at the Institute for Genomic Research (TIGR). His academic credentials include MIT Engineering Management with an emphasis on systems thinking and ML frameworks. As an IIJMB Wood-Whelan fellow, he is a joint PhD in Computational Biochemistry/Biophysics from the Indian Institute of Science (IISc) and the University of Texas, Austin, followed by post-doctoral work both at Yale and Harvard. He has extensively published in peer-reviewed journals and serves on scientific advisory committees.
Jim	LaRocque	Senior Research Scientist III, Assay Development & Screening	Curia	https://proventainternational.com/wp-content/uploads/2024/04/Jim-LaRocque.jpg	James LaRocque, Senior Research Scientist III, is leading a team of Curia’s biologists focused on providing state of the art screening and compound characterization platforms, including high content screening and cellular imaging analysis along with traditional cellular and biochemical technologies and label free screening by mass spectrometry detection as part of Curia’s integrated drug discovery center in Buffalo, NY. Previously he focused on the development and implementation of screening platform technologies and led characterization initiatives to identify selective inhibitors of critical Ubiquitin pathway enzymes. He led efforts in assay development, compound management, screening and hit characterization on hundreds of exploratory projects for Wyeth over his 20 year career which started with antiviral research and later diversified in to a wide variety of therapeutic areas while contributing to Wyeth’s and later Pfizer’s lead identification programs.
Tanweer	Khan	Senior Director, Head of Discovery Chemistry	aTai Life Sciences	https://proventainternational.com/wp-content/uploads/2024/02/Tanweer-Khan1.jpg	Dr. Tanweer Khan, Ph.D., is the Director of Discovery Chemistry at Atai Life Sciences since 2021. As the Head of Discovery Chemistry at Early Development, he provides senior leadership for various R&D organizations across multiple therapeutic areas. Dr. Khan coordinates research direction and oversees a diverse portfolio of psychedelic inspired/GPCR drug discovery programs with a focus on mental health, neuropsychiatric disorders, and neurodegenerative diseases. He excels in building high-performance internal and external CRO teams through effective communication, cross-functional collaboration, and fostering team creativity to drive synergy.
Dongming	Shen	Former Vice President, Chemistry	Viva Star Biosciences	https://proventainternational.com/wp-content/uploads/2024/02/Dongming-Shen.jpg	Dr. Dongming Shen started his industrial career at Mobil Oil’s Central Research Laboratory in Princeton, NJ. After five years at Mobil, he move to Merck at Rahway where he work on and led various medicinal chemistry projects over the next 21 years. After Merck, he moved to IFM therapeutics, where he discovered a NLRP3 antagonist which was moved into PhI trial after about 2 years at the company and it was sold to Novartis. After a brief stint at Odyssey Therapeutics, he is currently head of Global Chemistry at Viva Star Biosciences, a China based small molecule focused biotechnology company.
Yushma	Bhurruth-Alcor	Executive Director, Chemistry	Remedy Plan Therapeutics	https://proventainternational.com/wp-content/uploads/2024/04/Yushma.png	Yushma Bhurruth-Alcor joined Remedy Plan Therapeutics in 2018, where she is Executive Director, Chemistry. She brings extensive pharmaceutical drug discovery experience to the team, having worked in the pharmaceutical industry for companies such as GlaxoSmithKline, Galderma, and Johnson & Johnson, where she successfully developed novel clinical drug candidates. After graduating from the ESPCI in Paris, Yushma obtained her Ph.D. in Chemistry from Imperial College London. She has 15 years of experience in drug discovery and development, with extensive experience spanning a wide range of target classes (enzymes, ion channels, GPCRs, PPIs) across several therapeutic areas (oncology, dermatology, metabolic and respiratory diseases)

Abhijat Vatsyayan, Andrew Zhang, Christopher Conway, Mark Wolf, Matthew Surman, Helena Almqvist, Rick Ewing, Danny Talati, David James, Ernane Souza, PhD, RPh, Eileen Carry, Frank Leu, Gunaretnam Rajagopal, Huijun Wang, ML Ujwal, Jim LaRocque, Tanweer Khan, Dongming Shen, Yushma Bhurruth-Alcor

See the agenda and facilitator line-up. Download the strategy meeting brochure for full details.

DOWNLOAD THE BROCHURE

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

There’s only so much you can learn from presentations and lectures. Instead, our interactive Roundtable Discussions let you debate the topics that really matter.

Senior Decision Makers

All our Strategy Meetings are aimed at director-level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard.

Personalised Agendas

Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we’ll create a personalised agenda just for you.

Private and Intimate Networking

Small group discussions, private meetings, networking drink – however you choose to make those important connections, our Strategy Meetings have the solution.

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say...

Hotel & Venue

Hyatt Regency Princeton

Hyatt Regency Princeton hotel is conveniently located near corporate offices and attractions, as well as the Mercer County Airport.

Hotel Details Map & Directions Parking

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D New Jersey

Drug Discovery Biology & Bioinformatics Strategy Meeting East Coast 2024

Medicinal Chemistry

Strategy Meeting East Coast USA 2024

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Hyatt Regency Princeton

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our Facilitators

Abhijat Vatsyayan

Andrew Zhang

Christopher Conway

Mark Wolf

Matthew Surman

Helena Almqvist​​​​

Rick Ewing

Danny Talati

David James

Ernane Souza, PhD, RPh

Eileen Carry

Frank Leu

Gunaretnam Rajagopal

Huijun Wang

ML Ujwal

Jim LaRocque

Tanweer Khan

Dongming Shen

Yushma Bhurruth-Alcor

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our 2024 Sponsors

Lead Sponsor

Co-Host Sponsor

Partnering Sponsors

Key Opinion Leader

Media Partners

Become an official strategy meeting partner

Press play to hear what your colleagues had to say...

Hotel & Venue

Hyatt Regency Princeton

Want to find out more?

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Hyatt Regency Princeton

Helena Almqvist